Kura's COMZIFTI Achieves Majority Share in NPM1-mutant AML Launch

Second-quarter commercial progress and pipeline advances position Kura as a dual-franchise oncology leader

KURA · Earnings Call · 2026-08-12

A Commercial Inflection

Kura Oncology's second-quarter 2026 earnings call marked a decisive inflection point: the company's menin inhibitor COMZIFTI (ziftomenib) secured the majority share of new patient starts in the relapsed/refractory NPM1-mutant AML market just two quarters after commercial launch. The numbers speak to commercial execution: “In the second quarter, COMZIFTI generated $9.1 million in net product revenue, approximately 115 new patient starts more than 250 total prescriptions. Based on current prescription data COMZIFTI captured a majority share of new patient starts in the relapsed/refractory NPM1-mutant AML menin inhibitor market in only its second full quarter of launch.” — Brian T. Powl, Chief Commercial Officer · 2026-08-12 This is uncommon in oncology, especially for a second entrant. CEO Troy Wilson framed it as a validation of the product's differentiated profile: “Achieving majority share of new patient starts in only our second full commercial quarter. Despite entering the market second, it is clear evidence physicians are differentiating within the menin inhibitor class.” — Troy Edward Wilson, President and Chief Executive Officer · 2026-08-12 The new patient starts metric is the clearest leading indicator of future revenue, and Brian Powl highlighted that repeat prescribing is also growing: total prescriptions rose ~60% quarter-over-quarter. Importantly, physician-initiated combination use (with venetoclax/azacitidine or FLT3 inhibitors) already represents ~40% of starts, a signal that clinicians see COMZIFTI fitting into future treatment paradigms.

Pipeline Momentum Beyond the Launch

Beyond the launch, Kura is building a second franchise around darlifarnib. Data presented at ASCO and other meetings show the farnesyl transferase inhibitor enhances the activity of targeted therapy backbones across RCC and KRAS G12C solid tumors. In cabozantinib-naive clear cell RCC, objective response rates ranged from 33% to 50% with median PFS of 13 months; in a cabozantinib-exposed population, the ORR was 44% with a 94% disease control rate. The company is advancing FIT001, a randomized Phase 1b study, with enrollment expected to complete in H1 2027. The initiation of a daraxonrasib platform study in second-line or later KRAS-mutant pancreatic cancer is planned for the first half of 2027. The shared biology of darlifarnib—enhancing targeted therapy via MAP kinase pathway inhibition—positions it as a potential combination platform. As Troy Wilson summarized:

Stepping back, Kura is substantially stronger than it was even just 1 quarter ago. We have established commercial leadership in new patient starts in relapsed/refractory NPM1 mutant AML. We have built 1 of the most mature and robust frontline menin inhibitor data sets in AML We have advanced a wholly owned precision oncology platform beyond menin inhibition and we have maintained the financial strength to execute through multiple value creating milestones.
Troy Edward Wilson, President and Chief Executive Officer · 2026-08-12

The frontline program, KOMET-017, is enrolling ahead of plan, and management continues to guide to first topline data in 2028. The 12-month OS of 94% in the KOMET-007 frontline cohort compares favorably with historical 70-80% in younger fit patients, strengthening confidence in the registrational path.

Financial Trajectory and Catalysts

The company reported a net loss of $68.3M in Q2 (vs $66.1M a year ago) as SG&A ramped for the launch, while R&D remained stable at $61.9M. On a trailing basis, net losses have been widening steadily as Kura shifts from pure R&D to commercial execution. However, the balance sheet remains strong: cash and short-term investments of $519M plus an anticipated $180M from Kyowa Kirin collaboration fund operations through the 2028 readouts. The company reiterated collaboration revenue guidance of $45-55M for 2026, $90-110M for both 2027 and 2028. Prior quarter expectations set the stage: In the March 2026 call, Brian noted the launch would be measured by new patient starts; the actual 115 starts (vs 85 in Q1) exceeded the trajectory. As he reflected earlier: “We have reiterated before that our expectation is to get around 6 months of treatment. What I can say is that we are very pleased, of course, with the number of new patient starts. We think that is really the measurement at this early in the launch to measure how well we are doing. And think the 85 new patient starts sets us well.” — Brian T. Powl, Chief Commercial Officer · 2026-05-12 That momentum has now translated into tangible commercial leadership. Kura's story is not yet fully reflected in the tape: the stock has surged 37% over the last 90 days but remains far from its 2020 peak, suggesting investors are still pricing in substantial uncertainty around the frontline program and the breadth of darlifarnib's potential. Yet the company has delivered a compelling set of company-specific catalysts that are hard to dismiss.